GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease

Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype

Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease

This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease

Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill

The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers

Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients

HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors

£1bn London Cancer Hub expansion wins planning approval

The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site

Apotex scores exclusive Canadian rights to testosterone therapy Nebido

Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth

Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,

Lupin launches Topiramate ER capsules in US

Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR Extended-Release Capsules of Supernus Pharmaceuticals

Novo Nordisk weathers pricing pressure, bets big on oral Wegovy

Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates